Why the study?
Does the presence of congestive heart failure alter the pharmacokinetics of oral tocainide in patients with ventricular arrhythmias?
Does the presence of congestive heart failure alter the pharmacokinetics of oral tocainide in patients with ventricular arrhythmias?
The pharmacokinetics of oral tocainide do not significantly differ between patients with and without congestive heart failure, though small sample size limits definitive dosage recommendations.
No takes yet. Share an insight, caveat, or question.
May support unchanged tocainide dosing in heart failure; leaves open definitive recommendations pending larger studies.
Mohiuddin et al. (1983) studied this question.